Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 11/20 | 0.67 |
| ▸ | TGM2 | P21980 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30741210 | 0.80 | CES1 (0.50) | CES1TGM2MEN1POLBMAPT | |
| SCHEMBL2059124 | 0.80 | CES1 (0.50) | CES1TGM2MEN1POLBMAPT | |
| SCHEMBL734955 | 0.80 | CES1 (1.00) | CES1TGM2MEN1POLBMAPT | |
| SCHEMBL31103242 | 0.77 | CES1 (0.67) | CES1TGM2MEN1POLBMAPT | |
| SCHEMBL3391317 | 0.77 | CES1 (0.67) | CES1TGM2MEN1POLBMAPT | |
| SCHEMBL6177499 | 0.77 | CES1 (0.67) | CES1TGM2MEN1POLBMAPT | |
| SCHEMBL2372330 | 0.77 | CES1 (0.67) | CES1TGM2MEN1POLBMAPT | |
| SCHEMBL5738850 | 0.77 | CES1 (0.61) | CES1TGM2MEN1POLBMAPT | |
| SCHEMBL5329280 | 0.73 | CES1 (0.61) | CES1TGM2MEN1MAPTDUSP3 | |
| SCHEMBL29253561 | 0.71 | CES1 (0.69) | CES1TGM2MEN1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037909-B2 | Tetracyclic compounds as c-Met inhibitors | SUGEN, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1644362-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | SUGEN, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2005005378-A2 | INDOLINONE HYDRAZIDES AS C-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| WO-2005004808-A2 | TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS | SUGEN, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20050014755-A1 | Tetracyclic compounds as c-Met inhibitors | SUGEN INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014755-A1 | Tetracyclic compounds as c-Met inhibitors | MET, RET, HGF | CES1 1228/4885TGM2 584/4885MEN1 68/4885 |
| US-20060009493-A1 | Indolinone hydrazides as c-Met inhibitors | MET, IGF1R, ROS1 | CES1 1061/4885TGM2 2673/4885MEN1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.